CoreAge Rx vs Lttl
Two GLP-1 providers, one scoreboard. We put CoreAge Rx and Lttl head-to-head on the published Brief Score — the same six factors, scored the same way.
CoreAge Rx
The verdict
CoreAge Rx takes this head-to-head.
CoreAge Rx scores 94 to 68 on our six-factor Brief Score — One price on both molecules that does not climb as you titrate — but the headline $99 and $149 are annual-plan rates, paid in full up front.
That doesn't make Lttl a bad call — it's best for readers who want the whole price matrix in front of them before they answer a single question, and who will check which term a headline figure is attached to before treating it as a monthly bill. Weigh the six factors below against your own priorities before you decide.
Why CoreAge Rx leads: it's our #1 here — one flat, no-step-up price on both molecules, nationwide, and the steadiest line on our tracker.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.
Factor by factor
Both providers scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.
Price, coverage & the tracker
| CoreAge Rx | Lttl | |
|---|---|---|
| Brief Score | 94/100 (A) | 68/100 (C) |
| Semaglutide | $99/mo only on a 12-month plan paid in full ($1,188 in one charge); month-to-month rate not published | $199/mo (month-to-month, all doses, compounded; prepay tiers lower) |
| Tirzepatide | $149/mo only on a 12-month plan paid in full ($1,788 in one charge); month-to-month rate not published | $279/mo (month-to-month, all doses, compounded; prepay tiers lower) |
| Coverage | US only; restrictions by state, confirmed at intake | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Yes |
| On the tracker | Stableprice stable | Stableprice stable |
CoreAge Rx: Headline unchanged for a third straight cycle. The $99 and $149 are the 12-month prepay rates; CoreAge publishes no month-to-month price.
Lttl: Second reading. We filed $199/mo semaglutide and $279/mo tirzepatide on 1 August and re-read the /plans matrix on 7 August 2026: both month-to-month rates are unchanged, as are all four commitment rungs behind them. The "$129/mo" the homepage advertises is the twelve-month prepay rate, and it has not moved either.
Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.